Acadian Asset Management LLC Sells 282,314 Shares of Cambrex Co. (NYSE:CBM)
Acadian Asset Management LLC cut its position in shares of Cambrex Co. (NYSE:CBM) by 95.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,897 shares of the biotechnology company’s stock after selling 282,314 shares during the quarter. Acadian Asset Management LLC’s holdings in Cambrex were worth $578,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in CBM. Mackenzie Financial Corp increased its position in shares of Cambrex by 41.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,487,875 shares of the biotechnology company’s stock valued at $56,182,000 after purchasing an additional 434,406 shares during the last quarter. Norges Bank bought a new position in Cambrex during the 4th quarter worth approximately $12,632,000. BlackRock Inc. grew its position in Cambrex by 3.2% during the 4th quarter. BlackRock Inc. now owns 4,885,273 shares of the biotechnology company’s stock worth $184,469,000 after acquiring an additional 153,664 shares during the last quarter. Bank of New York Mellon Corp grew its position in Cambrex by 10.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,654,842 shares of the biotechnology company’s stock worth $62,487,000 after acquiring an additional 153,406 shares during the last quarter. Finally, Epoch Investment Partners Inc. bought a new position in Cambrex during the 4th quarter worth approximately $5,046,000.
Several equities analysts recently issued reports on the company. ValuEngine upgraded Cambrex from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Zacks Investment Research upgraded Cambrex from a “hold” rating to a “strong-buy” rating and set a $52.00 price target on the stock in a research report on Friday, May 10th. Robert W. Baird lowered Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 price target on the stock. in a research report on Friday, May 3rd. They noted that the move was a valuation call. First Analysis lowered Cambrex from a “strong-buy” rating to an “outperform” rating and raised their price target for the stock from $45.00 to $55.00 in a research report on Tuesday, May 7th. Finally, Jefferies Financial Group lowered Cambrex from a “buy” rating to a “hold” rating and set a $43.00 price target on the stock. in a research report on Friday, February 22nd. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $47.80.
Cambrex (NYSE:CBM) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.10. Cambrex had a return on equity of 12.25% and a net margin of 14.35%. The business had revenue of $159.46 million for the quarter, compared to analyst estimates of $159.71 million. During the same period last year, the company earned $0.72 EPS. Cambrex’s revenue for the quarter was up 13.0% compared to the same quarter last year. Research analysts forecast that Cambrex Co. will post 1.28 earnings per share for the current fiscal year.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Featured Story: What is the Federal Reserve?
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.